Loading organizations...
§ Private Profile · Hellerup, Hovedstaden, Denmark
Minervax is a technology company.
MinervaX is engaged in the clinical development of a Group B Streptococcal vaccine targeting pregnant women and older adults.
Minervax has raised $276.9M across 6 funding rounds.
Minervax has raised $276.9M in total across 6 funding rounds.
Minervax has raised $276.9M across 6 funding rounds. Most recently, it raised $57.3M Other Equity in October 2023.
MinervaX is a clinical-stage biotech company developing a prophylactic vaccine called AlpN GBS against Group B Streptococcus (GBS), a leading cause of life-threatening infections, stillbirths, and disabilities in newborns.[1][2][3][4][5] The vaccine targets maternal immunization to prevent adverse pregnancy outcomes, addressing an estimated 150,000 preventable infant deaths annually, with a protein-only design using fusions of immunogenic GBS surface proteins.[1][3][4][5] Founded in 2010 and based in Copenhagen, Denmark, the company has raised nearly €200M ($143M+), reached Series C stage, and completed Phase II trials in 470 pregnant women across Denmark, the UK, Uganda, and South Africa, positioning it for Phase III advancement.[1][4][5]
MinervaX was founded in 2010 in Copenhagen, Denmark, as a biotech focused on innovative vaccines against GBS, a pathogen causing severe newborn infections.[1][3][5] While specific founders are not detailed in available sources, leadership includes executives with deep vaccine expertise, such as a former CEO of LimmaTech Biologics—a spin-off from GlycoVaxyn, acquired by GSK in 2015—who advanced proprietary platforms and collaborated on related assets.[4] Pivotal early traction came from grants, investor syndicates, and loans totaling nearly €200M, enabling fast-tracked clinical development; key milestones include completing two Phase II trials (MVX0005) in 2023 and expanding labs in Lund for advanced assays and manufacturing.[1][4][5]
MinervaX rides the wave of maternal immunization vaccines, addressing unmet needs in global health where GBS causes ~150,000 preventable newborn deaths yearly, amplified by rising antimicrobial resistance and disparities in low-resource settings.[3][4] Timing aligns with post-pandemic vaccine tech advances and regulatory pushes for pregnancy-focused biologics, as seen in precedents like palivizumab filings.[4] Favorable market forces include grants/loans for neglected diseases and biotech M&A trends (e.g., GSK's past acquisitions), positioning MinervaX to influence neonatal health ecosystems by filling a critical gap—no approved GBS vaccine exists despite decades of need.[1][3][4][5]
MinervaX is primed for Phase III trials and potential commercialization of AlpN GBS, with ongoing manufacturing scale-up and team expansions in clinical, research, and finance to support regulatory filings.[4][5] Trends like AI-driven assays, global health funding, and expanding GBS indications (beyond newborns to adults) will shape its path, potentially leading to partnerships or acquisition by big pharma amid biotech consolidation.[1][4] Its influence could evolve from pioneer to market leader, dramatically cutting global stillbirths and inspiring protein-based vaccine platforms—transforming MinervaX from a high-need innovator into a life-saving standard.[3][4][5]
Minervax has raised $276.9M in total across 6 funding rounds.
Minervax's investors include Vincent Brichard, Tal Zaks, Adjuvant Capital, Industrifonden, LF Invest, Novo Holdings, Pureos Bioventures, Sanofi Ventures, Sunstone Life Science Ventures, Trill Impact, Wellington Partners, Andera Partners.